McKesson Corporation (MCK) - Q1 2026 (Ended June 30, 2025) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended June 30, 2025 (Q1 of Fiscal 2026). McKesson Corporation is a diversified healthcare services leader operating through four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The company reported a significant increase in revenue driven by market growth and strategic acquisitions, though net income declined year-over-year due to specific litigation provisions and reduced settlement gains.
Key Financial Metrics
| Metric | Q1 2026 (Current) | Q1 2025 (Prior Year) | Change |
|---|---|---|---|
| Revenues | $97,827 million | $79,283 million | +23% |
| Gross Profit | $3,279 million | $3,152 million | +4% |
| Gross Margin | 3.35% | 3.98% | -63 bps |
| Operating Income | $1,036 million | $1,029 million | +1% |
| Net Income (Attributable to MCK) | $784 million | $915 million | -14% |
| Diluted EPS | $6.25 | $7.00 | -11% |
| Operating Cash Flow | ($918 million) used | ($1,380 million) used | Improvement of $462M |
| Total Debt | $7,777 million | $5,654 million (Mar 31, 2025) | Increased due to new issuances |
| Cash & Equivalents | $2,418 million | $5,691 million (Mar 31, 2025) | Decreased due to M&A |
Material Changes vs. Prior Period
- Revenue Growth: Revenues surged 23% primarily due to volume growth in the U.S. Pharmaceutical segment (retail national accounts and specialty pharmaceuticals) and the inclusion of new acquisitions.
- Profitability Pressure: Despite revenue growth, Net Income declined 14%. This was driven by a $189 million provision for bad debts related to the Rite Aid bankruptcy, a decrease in antitrust settlement gains ($8M vs. $90M prior year), and higher restructuring charges ($47M vs. $10M).
- Acquisitions: The company completed two major acquisitions: PRISM Vision Holdings ($874M cash) and Core Ventures ($2.5B cash). These transactions significantly increased goodwill and intangible assets.
- Divestitures: The company completed the sale of its Canadian retail businesses (Rexall and Well.ca) and announced an agreement to sell its Norwegian retail and distribution businesses.
- Capital Allocation: The company returned $671 million to shareholders via $581 million in share repurchases and $90 million in dividends. The quarterly dividend was subsequently raised to $0.82 per share.
Outlook, Risks, and Management Commentary
- Restructuring Initiatives: Management approved enterprise-wide initiatives to modernize technology and improve efficiency, anticipating total charges of $650 million to $700 million through fiscal 2028.
- Strategic Separation: The company announced its intention to separate the Medical-Surgical Solutions segment into an independent company.
- Litigation Risks: Significant exposure remains regarding opioid-related litigation. The company has a total estimated liability of approximately $6.4 billion for opioid-related claims. While settlements with states and tribes are ongoing, the company is vigorously defending against non-governmental and remaining governmental claims.
- Rite Aid Bankruptcy: Following Rite Aid's second Chapter 11 filing in May 2025, McKesson recorded an additional $189 million provision for bad debts. Management believes current reserves are appropriate but notes potential for future adjustments.
- Liquidity: The company maintains access to a $4.0 billion revolving credit facility and a new $1.0 billion 364-day facility. Total debt increased to fund the Core Ventures acquisition, but the company remains in compliance with all covenants.
Investor Verification Checklist
- Rite Aid Exposure: Verify the sufficiency of the $189 million bad debt provision and potential for further write-offs as the bankruptcy proceedings evolve.
- Opioid Litigation Reserves: Review the $6.4 billion total estimated liability and the timeline for payments under various settlement agreements to assess long-term cash flow impact.
- Acquisition Integration: Monitor the financial performance and integration progress of PRISM Vision and Core Ventures, which were acquired mid-quarter.
- Medical-Surgical Spin-off: Track the timeline and terms for the announced separation of the Medical-Surgical Solutions segment.
- Debt Servicing: Assess the impact of the new long-term debt issuances ($2.0 billion) on future interest expense and leverage ratios.